Compare · HSDT vs MASI
HSDT vs MASI
Side-by-side comparison of Solana Company (HSDT) and Masimo Corporation (MASI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HSDT and MASI operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- MASI is the larger of the two at $9.36B, about 126.3x HSDT ($74.2M).
- Over the past year, HSDT is down 96.7% and MASI is up 4.6% - MASI leads by 101.3 points.
- HSDT has been more active in the news (14 items in the past 4 weeks vs 1 for MASI).
- MASI has more recent analyst coverage (24 ratings vs 3 for HSDT).
- Company
- Solana Company
- Masimo Corporation
- Price
- $1.38+9.52%
- $179.96+0.63%
- Market cap
- $74.2M
- $9.36B
- 1M return
- -36.11%
- +0.83%
- 1Y return
- -96.71%
- +4.56%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2007
- News (4w)
- 14
- 1
- Recent ratings
- 3
- 24
Solana Company
Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. Its product, Portable Neuromodulation Stimulator (PoNS), is a non-implantable investigational medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company is headquartered in Newtown, Pennsylvania.
Masimo Corporation
Masimo Corporation develops, manufactures, and markets noninvasive monitoring technologies and hospital automation solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry. It also provides Masimo rainbow SET platform that includes rainbow SET Pulse CO-Oximetry products that noninvasively monitor hemoglobin species, including oxygen saturation, pulse rate, perfusion index, pleth variability index, and respiration rate from the pleth; noninvasively monitor hemoglobin concentration, and carboxyhemoglobin and methemoglobin; monitor arterial oxygen saturation and acoustic respiration rate; and calculates oxygen content and oxygen reserve index. The company offers SedLine brain function monitoring technology to measure the brain's electrical activity by detecting EEG signals; capnography and gas monitoring products comprising external plug-in-and-measure capnography and gas analyzers, integrated modules, handheld capnograph and capnometer devices, and capnography sampling lines; O3 regional oximetry for tissue oxygen saturation measurement; and hemodynamic monitoring solutions. Its Masimo Hospital Automation platform includes Patient SafetyNet, Patient SafetyNet surveillance, Kite, UniView, Replica, UniView : 60, and MyView. The company offers coronavirus-2019 response and telehealth solutions; connectivity devices; and nasal high flow ventilation and neuromodulation solutions. The company provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, physician offices, long term care facilities, veterinarians, and consumers; and non-medical/consumer products through e-commerce site, masimopersonalhealth.com. Incorporated in 1989, the company is headquartered in Irvine, California.
Latest HSDT
- Director Jiang Cosmo Yi exercised 1,005,040 shares at a strike of $0.00 and covered exercise/tax liability with 610 shares (SEC Form 4)
- SEC Form 4 filed by Director Jiang Cosmo Yi
- Solana Company filed SEC Form 8-K: Entry into a Material Definitive Agreement
- SEC Form 424B5 filed by Solana Company
- SEC Form SD filed by Solana Company
- Director Straw Edward M was granted 6,360 shares, increasing direct ownership by 291% to 8,542 units (SEC Form 4)
- Director Mello Sergio was granted 6,360 shares (SEC Form 4)
- Director Lee Michel Kai Tai was granted 6,360 shares (SEC Form 4)
- Director Walter Blane was granted 6,360 shares, increasing direct ownership by 291% to 8,542 units (SEC Form 4)
- Amendment: Director Straw Edward M was granted 2,180 shares, increasing direct ownership by 109,000% to 2,182 units (SEC Form 4)
Latest MASI
- SEC Form SD filed by Masimo Corporation
- SEC Form SCHEDULE 13G filed by Masimo Corporation
- SEC Form 10-Q filed by Masimo Corporation
- Director Scannell Timothy J converted options into 1,225 shares, increasing direct ownership by 89% to 2,608 units (SEC Form 4)
- Director Lane Wendy E converted options into 1,225 shares, increasing direct ownership by 89% to 2,608 units (SEC Form 4)
- Chairman of the Board Brennan Michelle converted options into 1,225 shares, increasing direct ownership by 17% to 8,543 units (SEC Form 4)
- Chief Human Resources Officer Hellmann Elisabeth A converted options into 335 shares and covered exercise/tax liability with 121 shares (SEC Form 4) to satisfy tax liability
- Masimo Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits
- Masimo Shareholders Approve Acquisition by Danaher
- Amendment: SEC Form 10-K/A filed by Masimo Corporation